Fig. 4
HER4 promotes trastuzumab resistance in vivo and inducing EMT by regulating YAP1. a Tumor samples of the two groups were collected 30 days after 2 × 106 MKN45TR-NC and MKN45TR-siHER4 cells subcutaneous implantations when tumor sizes reached the sacrificed endpoints. The sizes of the tumors were measured in triplicated. b Representative figures from the subcutaneous tumor IHC analysis of HER4, p-HER4, YAP1, E-Cadherin, and Vimentin are shown. c 1 × 105 MKN45TR-NC or MKN45TR-siHER4 cells were injected by tail vein for 30 days and the magnified areas indicate the areas with metastatic nodes by HE staining. d Western blot analysis of the potential downstream target YAP1 of HER4 for MKN45TR and NCI-N87TR cells with or without transfection of siHER4. e Q-PCR analysis of relative YAP1 mRNA levels in MKN45TR and NCI-N87TR cells transfected with NC or siHER4 for 24 h. f Immunofluorescence of YAP1 expression after the siHER4 was transfected into MKN45TR or NCI-N87TR cells for 24 h. g The interaction between HER4 and YAP1 was measured by co-immunoprecipitation analysis
